Notice2023-21365
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 29, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 188 (Friday, September 29, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 188 (Friday, September 29, 2023)]
[Notices]
[Page 67325]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-21365]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Initial
Review Group Medication Development Research Study Section.
Date: November 15, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301-443-
4577, <a href="/cdn-cgi/l/email-protection#0769667e667577354764747529696e6f29606871"><span class="__cf_email__" data-cfemail="e9878890889b99dba98a9a9bc7878081c78e869f">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel, NIDA Avant-Garde Program for HIV and Substance Use
Disorder Research.
Date: December 5-6, 2023.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892 (301) 496-9350,
<a href="/cdn-cgi/l/email-protection#097a616c6065682779607b66667367606849676061276e667f"><span class="__cf_email__" data-cfemail="b3c0dbd6dadfd29dc3dac1dcdcc9dddad2f3dddadb9dd4dcc5">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 25, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-21365 Filed 9-28-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 29, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.